KWM
PACB icon

Kingsview Wealth Management’s Pacific Biosciences PACB Stock Holding History

Kingsview Wealth Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.2K Buy
10,765
+331
+3% +$592 ﹤0.01% 1326
2025
Q4 		$19.5K Buy
+10,434
New +$20.1K ﹤0.01% 1228

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Kingsview Wealth Management's PACB Position: Q1 2026 in Review

Kingsview Wealth Management increased its Pacific Biosciences (PACB) stake by 3.2% in Q1 2026, buying an estimated $592 and bringing the position to 10,765 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1326.

Kingsview Wealth Management first reported a position in PACB in Q4 2025 and has held it in 2 quarters since. The position peaked at $19.5K in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Kingsview Wealth Management held 10,765 shares of Pacific Biosciences worth $14.2K as of Q1 2026.
  • Kingsview Wealth Management bought 331 Pacific Biosciences shares in Q1 2026, an estimated $592.
  • Pacific Biosciences made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q1 2026, its #1326 holding.
  • Kingsview Wealth Management first reported a position in Pacific Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Kingsview Wealth Management's Pacific Biosciences position peaked at $19.5K in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.